ArticleBMC medical imaging2026
Predicting local control of brain metastases after Gamma Knife radiosurgery: a multimodal deep learning-radiomics approach.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-habitat radiomics on T2-FS MRI for identifying spatial patterns of axial spondyloarthritis-associated bone marrow edema.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAccurate prediction of local control (LC) following Gamma Knife radiosurgery (GKRS) remains clinically challenging for patients with brain metastases (BMs) secondary to breast or lung cancer. The scarcity of validated pre-therapeutic biomarkers currently hinders the development of individualized treatment decision-making strategies.
methodsThis retrospective analysis included 324 BMs from 195 patients. To develop and benchmark various predictive frameworks, several models were constructed: clinical-only, radiomics-only, 2D deep learning (DL)-only, fused radiomics-DL (DLR), and a Combined model integrating all three modalities (clinical, radiomic, and DL features). All imaging signatures were derived from pre-treatment contrast-enhanced T1-weighted (T1CE) magnetic resonance imaging (MRI). Model performance was evaluated using the area under the curve (AUC), calibration plots, the Hosmer-Lemeshow test, and decision curve analysis (DCA).
resultsThe Combined model demonstrated consistently high numerical discriminative performance, achieving an AUC of 0.854 (95% Confidence Interval [CI]: 0.791-0.917) in the training cohort and 0.781 (95% CI: 0.618-0.945) in the independent test cohort. DCA demonstrated that the Combined model yielded superior net clinical benefit across threshold probabilities ranging from 10% to 50%, outperforming all other candidate models. Consequently, a nomogram based on the Combined model was developed to facilitate individualized risk estimation.
conclusionsThe integration of clinical parameters, handcrafted radiomic features, and 2D deep learning signatures provides a robust predictive tool for LC following GKRS in patients with brain metastases from breast or lung cancer. This multimodal approach holds significant potential for refining post-radiosurgical management and advancing personalized neuro-oncology care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.